Key facts
- Achira’s last known valuation is $35.0M (Feb 2025).
- It has raised $33.0M; the latest was Seed Round ($33.0M) in Feb 2025.
- Notable investors include Nvidia, Amplify Partners, Dimension (United States), Compound (California).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Achira
- ·The full record, as it builds
Funding rounds
No funding rounds for Achira are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Achira
Operator of a biotechnology company intended to power the future of drug discovery. The company offers atomistic foundation simulation models which are significantly limited by the paucity and cost of acquisition of drug discovery data and deliver unprecedented performance across a diverse set of biomolecular applications, enabling clients to get therapeutic compounds.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2024
- Employees
- 13
- Website
- achira.ai/
- Ownership
- Privately Held (backing)
Achira doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Achira shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Achira in its N-PORT filings yet. We sweep new filings monthly.